Novartis multiple sclerosis drug remibrutinib shows weaker-than-expected relapse reduction
Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.
